OxyContin, prescription opioid abuse and economic medicalization

References

• Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99:221–227.
   PubMed Web of Science ®Google Scholar
• Government Accounting Office. OxyContin abuse and diversion and efforts to address the problem: highlights of a government report. J Pain Palliat Care Pharmacother. 2004;18:109–113.
   Google Scholar
• Government Accounting Office. OxyContin Abuse and Diversion and Efforts to Address the Problem. Washington, DC: GAO; 2003.
   Google Scholar
• Poitras G, Meredith L. Ethical transparency and economic medicalization. J Bus Ethics. 2009;86:313–325.
   Web of Science ®Google Scholar
• Conrad P. The Medicalization of Society. Baltimore, MD: Johns Hopkins Press; 2007.
   Google Scholar
• Conrad P. The shifting engines of medicalization. J Health Soc Behav. 2005;46:3–14.
   PubMed Web of Science ®Google Scholar
• Conrad P, Leiter V. Medicalization, markets and consumers. J Health Soc Behav. 2004;45 Suppl:158–176.
   PubMed Web of Science ®Google Scholar
• Poitras G. Medical ethics and economic medicalization. In: Clark P, editor. Contemporary Issues in Bioethics. Rijeka, Croatia: InTech; 2012.
   Google Scholar
• Poitras G. Business ethics, medical ethics and economic medicalization. Int J Bus Govern Ethics. 2009;4:372–389.
   Google Scholar
• Moloney M, Konrad T, Zimmer C. The medicalization of sleeplessness: a public health concern. Am J Public Health. 2011;101:1429–1433.
   PubMed Web of Science ®Google Scholar
• Poitras G. Shareholder wealth maximization, business ethics and social responsibility. J Bus Ethics. 1994;13:125–134.
   Web of Science ®Google Scholar
• Executive Office of the President of the United States. Epidemic: Responding to America’s Prescription Drug Abuse Crisis. 2011. Available from: http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan.pdf. Accessed October 25, 2012.
   Google Scholar
• Wootton B. Social Science and Social Pathology. New York, NY: Macmillan; 1959.
   Google Scholar
• Szasz T. Psychiatry, ethics, and the criminal law. Columbia Law Rev. 1958;58:183–198.
   Web of Science ®Google Scholar
• Szasz T. Scientific method and social role in medicine and psychiatry. AMA Arch Intern Med. 1958;101:228–238.
   Google Scholar
• Szasz T. The Myth of Mental Illness. New York, NY: Harper and Row; 1961.
   Google Scholar
• Parsons T. The Social System. New York, NY: Free Press; 1951.
   Google Scholar
• Davis J. How medicalization lost its way. Society. 2006;43:51–56.
   Web of Science ®Google Scholar
• Freidson E. Profession of Medicine. New York, NY: Dodd, Mead; 1970.
   Google Scholar
• Zola I. Medicine as a institution of social control. Sociol Rev. 1972;20: 487–504.
   PubMed Web of Science ®Google Scholar
• Conrad P. Medicalization and social control. Annu Rev Sociol. 1992;18: 209–232.
   Web of Science ®Google Scholar
• Sismondi S. Pharmaceutical maneuvers. Soc Stud Sci. 2004;34: 149–159.
   Web of Science ®Google Scholar
• Healy D. Shaping the intimate: influences on the experience of everyday nerves. Soc Stud Sci. 2004;34:219–245.
   PubMed Web of Science ®Google Scholar
• Avorn J. Dangerous deception – hiding the evidence of adverse drug effects. New Engl J Med. 2006;355:2169–2171.
   PubMed Web of Science ®Google Scholar
• Jones G, Hagtvedt R. Marketing in heterozygous advantage. J Bus Ethics. 2008;77:85–87.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses – a US epidemic. MMWR Morb Mortal Wkly Rep. 2012;61:10–13.
   PubMedGoogle Scholar
• American Medical Association. Code of Medical Ethics of the American Medical Association: Current Opinions with Annotations 2010–2011. Chicago, IL: American Medical Association; 2010.
   Google Scholar
• McCullough L John Gregory and the Invention of Professional Medical Ethics and the Profession of Medicine. Dordrecht, Netherlands: Kluwer; 1998.
   Google Scholar
• Eaton M. Ethics and the Business of Bioscience. Stanford, CA: Stanford University Press; 2004.
   Google Scholar
• Eaton M. Managing the risks associated with using biomedical ethics advice. J Bus Ethics. 2008;77:99–109.
   Web of Science ®Google Scholar
• Moynihan R, Cassels A. Selling Sickness: How the World’s Biggest Pharmaceutical Companies Are Turning Us All into Patients. Vancouver, BC: Greystone; 2005.
   Google Scholar
• Brennan R, Eagle L, Rice D. Medicalization and marketing. J Macromarketing. 2010;30:8–22.
   Web of Science ®Google Scholar
• Caplovitz A. Turning Medicine into Snake Oil: How Pharmaceutical Marketers Put Patients at Risk. Trenton, NJ: New Jersey Public Interest Research Group Law and Policy Center; 2006.
   Google Scholar
• Angell M. The Truth About Drug Companies: How They Deceive Us and What to Do about It. New York, NY: Random House; 2004.
   Google Scholar
• Meier B. Pain Killer. Emmaus, PA: Rodale; 2003.
   Google Scholar
• Porter J, Jick H. Addiction rare in patients treated with narcotics. New Engl J Med. 1980;302:123.
   PubMed Web of Science ®Google Scholar
• Perry S, Heidrich G. Management of pain during debridement: a survey of US burn units. Pain. 1982;13:267–280.
   PubMed Web of Science ®Google Scholar
• Donohue J, Cevasco M, Rosenthal M. A decade of direct-to-consumer advertising of prescription drugs. New Engl J Med. 2007;357: 673–681.
   PubMed Web of Science ®Google Scholar
• Greene J. Attention to ‘details’: etiquette and the pharmaceutical salesmen in postwar USA. Soc Stud Sci. 2004;34:271–292.
   PubMed Web of Science ®Google Scholar
• Chew L, O’Young T, Hazlet T, Bradley K, Maynard C, Lessler D. A physician survey of the effect of drug sample availability on physicians’ behavior. J Gen Intern Med. 2000;15:478–483.
   PubMed Web of Science ®Google Scholar
• Campbell E. Doctors and drug companies: scrutinizing influential relationships. New Engl J Med. 2007;357:1796–1797.
   PubMed Web of Science ®Google Scholar
• Warner M, Chen L, Makuc D, Anderson R, Miniño A Drug poisoning deaths in the United States, 1980–2008. NCHS Data Brief. 2011:81.
   Google Scholar
• Lofwall M, Moody D, Fang W, Nuzzo P, Walsh S. Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in non-dependent prescription opioid abusers. J Clin Pharmacol. 2012;52: 600–606.
   Web of Science ®Google Scholar
• Carise D, Dugosh K, McLellan A, Camilleri A, Woody G, Lynch K. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164:1750–1756.
   PubMed Web of Science ®Google Scholar
• Jones J, Vosburg S, Manubay M, Comer S. Oxycodone abuse in New York City: characteristics of intravenous and intranasal users. Am J Addict. 2011;20:190–195.
   PubMed Web of Science ®Google Scholar
• Jonas A, Young A, Oser C, Leukefeld C, Havens J. OxyContin as currency: OxyContin use and increased social capital among rural Appalachian drug users. Soc Sci Med. 2012;74:1602–1609.
   PubMed Web of Science ®Google Scholar
• Cicero T, Inciardi J, Munoz A. Trends in the abuse of OxyContin and other analgesics in the United States: 2002–2004. J Pain. 2005;6: 662–672.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Overdose deaths involving prescription opioids among Medicaid enrollees – Washington, 2004–2007. MMWR Morb Mortal Wkly Rep. 2009;58:1171–1175.
   PubMedGoogle Scholar
• Levy M. An exploratory study of OxyContin use among individuals with substance use disorders. J Psychoactive Drugs. 2007;39:271–276.
   PubMed Web of Science ®Google Scholar
• Sees K, Di Marino M, Ruediger N, Sweeney C, Shiffman S. Non-medical use of OxyContin tablets in the United States. J Pain Palliat Care Pharmacother. 2005;19:13–23.
   PubMedGoogle Scholar
• Grau L, Dasgupta N, Harvey A, et al. Illicit use of opioids: is OxyContin a ‘gateway drug’? Am J Addict. 2007;16:166–173.
   PubMed Web of Science ®Google Scholar
• Hays L. A profile of OxyContin addiction. J Addict Dis. 2004;23: 1–9.
   PubMed Web of Science ®Google Scholar
• Rawson R, Maxwell J, Rutkowski B. OxyContin abuse: who are the users? Am J Psychiatry. 2007;164:1634–1636.
   Web of Science ®Google Scholar
• Swann J. Drug abuse control under FDA, 1938–1968. Public Health Rep. 1997;112:83–86.
   Web of Science ®Google Scholar
• Cicero T, Ellis M, Surratt H. Effect of abuse-deterrent formulation of OxyContin. New Engl J Med. 2012;367:187–189.
   PubMed Web of Science ®Google Scholar